OTLK FDA calendar & decision history Outlook Therapeutics, Inc. · 1 upcoming · 4 past FDA decisions
Upcoming FDA catalysts OTLK · Jul 29, 2026 bevacizumab — Neovascular Age-related Macular Degeneration FDA decision history (4) Apr 7, 2026✕ CRL LYTENAVA (bevacizumab-vikg) / Mar 5, 2026✕ CRL LYTENAVA (bevacizumab-vikg) / Dec 31, 2025✕ CRL FDA decision Aug 28, 2025✕ CRL source-verified See the full 2026 PDUFA calendar → This page aggregates OTLK's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent service; "FDA", "PDUFA", and all company, drug, and ticker names are used descriptively and remain the property of their owners. Informational and educational only — not investment advice. Data and historical statistics only; no trade recommendations and no individual-drug approval probabilities. Verify every date and outcome against primary FDA / SEC / company filings. © 2026 pdufa.bio